Leora B. Balsam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Leora B. Balsam has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Robert C. Robbins
Department of Cardiothoracic Surgery, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, U.S.A.
3 shared publications- Theo Kofidis
Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117599, Singapore
2 shared publications David T. Cooke
1 shared publicationE. Grant Hoyt
1 shared publicationG. Kimia Mokhtari
1 shared publicationMarc P. Pelletier
Stanford Program in Cardiac Surgery at El Camino Hospital, Mountain View, California
1 shared publication
Latest Publications
- 27 October 2008
- Published by Hindawi Limited in Journal of Cardiac Surgery
- Vol. 23 (6) , 614-621
Factor Eight Inhibitor Bypassing Activity (FEIBA) for Refractory Bleeding in Cardiac Surgery: Review of Clinical Outcomes
Refractory postoperative bleeding complicates a significant number of cardiac surgical procedures and results in both morbidity and mortality. Conventional strategies to effect hemostasis include surgical reexploration and administration of blood products. In some cases, bleeding remains intractable despite these methods, and alternatives are needed. Herein, we report our experience with the use of factor eight inhibitor bypassing activity (FEIBA), a coagulation factor concentrate, for refractory postoperative bleeding. A retrospective review of the experience with FEIBA at a university-affiliated cardiac surgery program between February 2004 and January 2007 was performed. Sixteen patients received FEIBA for refractory postoperative bleeding. The majority (69%) received a single dose, either intraoperatively or postoperatively. The recipients of multiple doses were more likely to undergo operative reexploration. Blood product utilization and hourly chest tube output were decreased significantly following administration of FEIBA. Three deaths occurred (19%), two from multisystem organ failure and one from respiratory failure. Thrombotic events included the development of a clotted hemothorax in one patient and distal extremity ischemia in another. FEIBA administration is associated with decreased blood product utilization and chest tube output in patients with refractory postoperative bleeding.
- 27 October 2008
- Published by Hindawi Limited in Journal of Cardiac Surgery
- Vol. 23 (6) , 614-621
Factor Eight Inhibitor Bypassing Activity (FEIBA) for Refractory Bleeding in Cardiac Surgery: Review of Clinical Outcomes
Refractory postoperative bleeding complicates a significant number of cardiac surgical procedures and results in both morbidity and mortality. Conventional strategies to effect hemostasis include surgical reexploration and administration of blood products. In some cases, bleeding remains intractable despite these methods, and alternatives are needed. Herein, we report our experience with the use of factor eight inhibitor bypassing activity (FEIBA), a coagulation factor concentrate, for refractory postoperative bleeding. A retrospective review of the experience with FEIBA at a university-affiliated cardiac surgery program between February 2004 and January 2007 was performed. Sixteen patients received FEIBA for refractory postoperative bleeding. The majority (69%) received a single dose, either intraoperatively or postoperatively. The recipients of multiple doses were more likely to undergo operative reexploration. Blood product utilization and hourly chest tube output were decreased significantly following administration of FEIBA. Three deaths occurred (19%), two from multisystem organ failure and one from respiratory failure. Thrombotic events included the development of a clotted hemothorax in one patient and distal extremity ischemia in another. FEIBA administration is associated with decreased blood product utilization and chest tube output in patients with refractory postoperative bleeding.
- Open Access
- 1 June 2007
- Published by SAGE Publications in Scandinavian Journal of Surgery
- Vol. 96 (2) , 125-130
Current Trends in Heart Transplantation
Inhibitor allergies), beta-blocker (metoprolol or carvedilol), digoxin,a nd an aldosterone antagonist. For patients with an ejection fraction (EF) less than 35% and QRS >120 msec, cardiac resynchronization therapy with ab iventricular pacemaker should be attempted.H eart transplantation is considered in patients with medically optimized NYHA classIII and IV heart failure, recurrent life-threatening arrhythmias despitea nI CD, medically refractory angina with no option for revascularization, or cardiogenic shock requiring intravenous inotropes or mechanical support (3, 4). Common underlying diagnosesi n these patients includei diopathic dilatedc ardiomyopathy (45%), ischemic cardiomyopathy (42%), valvular heart disease (3%), congenital heart disease (2%), and and post-transplant coronary artery vasculopathy (2%) (2). The evaluation process includes review of clinical and psychosocial data by am ultidisciplinary transplant team. Many factors influence eligibility for heart transplantation,i ncluding the degree of cardiopulmonary impairment, comorbidm edical conditions, age, history of medical compliance, and social support (Table 1). Standardw ork-up includes ah istory and physical, psychosocial assessment,l aboratory studies, pulmonary function tests, and cardiovascular evaluation. The cardiovascular work-up includes electrocardiography,e chocardiography, and right heart catheterization. Other studies, including left heart catheterization, endomyocardial biopsy,radionuclide ventriculography,a nd Holter monitoring may be indicated in some cases. For outpatients, peak exercise oxygen consumption (VO 2)testing is auseful correlatefor cardiacfunction. AVO 2 15ml/kg/min should undergo repeat testing every 3-6 months. Contraindications to transplantation include irreversible pulmonary hypertension (PVR >3-4 Wood units despite vasodilator therapy), significant renal or hepatic impairment, active infection, active malignancy,H IV,a nd diabetes with end-organ damage. Patients with irreversible pulmonary hypertension may be candidates for heart-lung transplantation, and rarely, those with significant renal or hepatic dys
- 1 June 2007
- Published by SAGE Publications in Scandinavian Journal of Surgery
- Vol. 96 (2) , 125-130
Open AccessCurrent Trends in Heart Transplantation
Inhibitor allergies), beta-blocker (metoprolol or carvedilol), digoxin,a nd an aldosterone antagonist. For patients with an ejection fraction (EF) less than 35% and QRS >120 msec, cardiac resynchronization therapy with ab iventricular pacemaker should be attempted.H eart transplantation is considered in patients with medically optimized NYHA classIII and IV heart failure, recurrent life-threatening arrhythmias despitea nI CD, medically refractory angina with no option for revascularization, or cardiogenic shock requiring intravenous inotropes or mechanical support (3, 4). Common underlying diagnosesi n these patients includei diopathic dilatedc ardiomyopathy (45%), ischemic cardiomyopathy (42%), valvular heart disease (3%), congenital heart disease (2%), and and post-transplant coronary artery vasculopathy (2%) (2). The evaluation process includes review of clinical and psychosocial data by am ultidisciplinary transplant team. Many factors influence eligibility for heart transplantation,i ncluding the degree of cardiopulmonary impairment, comorbidm edical conditions, age, history of medical compliance, and social support (Table 1). Standardw ork-up includes ah istory and physical, psychosocial assessment,l aboratory studies, pulmonary function tests, and cardiovascular evaluation. The cardiovascular work-up includes electrocardiography,e chocardiography, and right heart catheterization. Other studies, including left heart catheterization, endomyocardial biopsy,radionuclide ventriculography,a nd Holter monitoring may be indicated in some cases. For outpatients, peak exercise oxygen consumption (VO 2)testing is auseful correlatefor cardiacfunction. AVO 2 15ml/kg/min should undergo repeat testing every 3-6 months. Contraindications to transplantation include irreversible pulmonary hypertension (PVR >3-4 Wood units despite vasodilator therapy), significant renal or hepatic impairment, active infection, active malignancy,H IV,a nd diabetes with end-organ damage. Patients with irreversible pulmonary hypertension may be candidates for heart-lung transplantation, and rarely, those with significant renal or hepatic dys
- 23 November 2005
- Published by Portland Press Ltd. in Clinical Science
- Vol. 109 (6) , 483-492
Haematopoietic stem cells and repair of the ischaemic heart
HSCs (haematopoietic stem cells) are multipotent stem cells that give rise to all cells of the blood cell lineage. In recent years, it has been proposed that bone marrow serves as a reservoir for cardiomyogenic precursors and that, following cardiac injury, these stem cells circulate to the site of injury where they contribute to myocardial repair and regeneration. This concept of stem cell plasticity has been controversial and, in fact, several key studies on the cardiomyogenic potential of HSCs have not been reproducible in the hands of independent investigators. Despite this controversy, the clinical community has pushed forward with clinical trials of bone marrow transplantation for the treatment of ischaemic heart disease. The following review summarizes the mechanistic underpinnings of bone marrow transplantation into ischaemic myocardium, focusing on the basic science that forms the foundation of this field, and highlights the controversies and new avenues for research that have emerged. It also describes the current state of the art in clinical trials of bone marrow transplantation for heart failure.
- 23 November 2005
- Published by Portland Press Ltd. in Clinical Science
- Vol. 109 (6) , 483-492
Haematopoietic stem cells and repair of the ischaemic heart
HSCs (haematopoietic stem cells) are multipotent stem cells that give rise to all cells of the blood cell lineage. In recent years, it has been proposed that bone marrow serves as a reservoir for cardiomyogenic precursors and that, following cardiac injury, these stem cells circulate to the site of injury where they contribute to myocardial repair and regeneration. This concept of stem cell plasticity has been controversial and, in fact, several key studies on the cardiomyogenic potential of HSCs have not been reproducible in the hands of independent investigators. Despite this controversy, the clinical community has pushed forward with clinical trials of bone marrow transplantation for the treatment of ischaemic heart disease. The following review summarizes the mechanistic underpinnings of bone marrow transplantation into ischaemic myocardium, focusing on the basic science that forms the foundation of this field, and highlights the controversies and new avenues for research that have emerged. It also describes the current state of the art in clinical trials of bone marrow transplantation for heart failure.
- 1 July 2005
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 24 (7) , 827-832
Early Inhibition of Caspase-3 Activity Lessens the Development of Graft Coronary Artery Disease
- 1 July 2005
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 24 (7) , 827-832
Early Inhibition of Caspase-3 Activity Lessens the Development of Graft Coronary Artery Disease
- 1 April 2005
- Published by Elsevier in Journal of Surgical Research
- Vol. 124 (2) , 194-200
Caspase-3 inhibition preserves myocardial geometry and long-term function after infarction
- 1 April 2005
- Published by Elsevier in Journal of Surgical Research
- Vol. 124 (2) , 194-200
Caspase-3 inhibition preserves myocardial geometry and long-term function after infarction